Astellas Pharma : Supplementary Documents (FY2021)

Supplementary Documents [IFRS]

Financial results for the fiscal year 2021 (FY2021)

Astellas Pharma Inc.

• - FY2021 Financial Results

  •  For the year ended March 31, 2022

  •  Three months ended March 31, 2022

• - Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

-

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2022]

1. Consolidated Results (Full Basis)

Revenue Cost of salesGross profit SG&A expensesXTANDI co-promotion fee in the United states Personnel expenses

Advertising and Sales Promotion and Other R&D expenses

Amortisation of intangible assets

Gain on divestiture of intangible assets

Ratio to RevenueRatio to RevenueRatio to Revenue

Share of profit (loss) of investments accounted for using equity method

Other income

Net foreign exchange gains

Fair value remeasurements on contingent consideration Other expense

Impairment losses Restructuring costs

Net foreign exchange losses

Fair value remeasurements on contingent consideration Operating profit

Finance income Finance expenses Profit before taxIncome tax expense ProfitComprehensive income

Ratio to RevenueRatio to RevenueRatio to Revenue

Change fromUnit: B¥

Forecasts

Forecasts

FY21

FY22 Full Year	Change (%)
1,443.0	11.3%
598.0 41.4% 182.0 254.0 17.6%	9.0% 30.6% 3.2%
269.0 18.6%	72.8%
267.0 18.5%	70.2%
208.0 14.4%	67.6%

182.0

Change from

2. Consolidated Results (Core Basis)

Share of profit (loss) of investments accounted for using equity method

Revenue Cost of salesGross profit SG&A expensesXTANDI co-promotion fee in the United states Personnel expenses

Advertising and Sales Promotion and Other R&D expenses

Gain on divestiture of intangible assets Amortisation of intangible assets

Operating profit

Finance income Finance expenses Profit before taxIncome tax expense Profit

Ratio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to Revenue

Unit: B¥

Forecasts

Forecasts

FY21

FY22 Full Year	Change (%)
1,443.0	11.3%
598.0 41.4% 182.0 254.0 17.6%	9.0% 30.6% 3.2%
290.0 20.1%	18.5%
223.0 15.5%	17.0%

182.0

3. Exchange Rate

FY20 Ave.

USD/Yen EUR/Yen

* Fx impacts: Revenue +59.6 billion yen and Core operating profit +18.5 billion yen

* Fx impact on elimination of unrealized gain: COGs ratio +0.2ppt

FY21 Ave.

106 124

112 131

FY20 End

111 130

Unit: yen

Forecasts

Forecasts

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

FY20 Full year	FY21 Full year
Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	1,249.5	-	1,249.5	1,296.2	-	1,296.2
Cost of sales	246.1	-	246.1	253.0	-	253.0
Gross profit	1,003.5	-	1,003.5	1,043.2	-	1,043.2
SG&A expenses R&D expenses Amortisation of intangible assets Gain on divestiture of intangible assets Share of profit (loss) of investments accounted for using equity method Other income * Other expenses *	504.3 224.5 23.8 - 0.5 7.6 123.0	- - - - - -7.6 -123.0	504.3 224.5 23.8 - 0.5 - -	548.8 246.0 28.3 24.2 0.5 15.3 104.3	- - - - - -15.3 -104.3	548.8 246.0 28.3 24.2 0.5 - -
Operating profit	136.1	115.3	251.4	155.7	89.1	244.7
Finance income Finance expenses	11.6 2.3	- -	11.6 2.3	6.1 4.9	- -	6.1 4.9
Profit before tax	145.3	115.3	260.6	156.9	89.1	245.9
Income tax expense	24.7	26.0	50.7	32.8	22.6	55.4
Profit	120.6	89.3	209.9	124.1	66.5	190.6

* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

Change from

5. Revenue by RegionRevenue

Japan United States Established Markets Greater China International Markets Others

Ratio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to Revenue

• - Established Markets: Europe, Canada, Australia

• - Greater China: China, Hong Kong, Taiwan

• - International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc

6. Per Share Information

The number of shares issued after deducting Treasury Shares (thousand)

The number of shares issued (thousand)

Treasury Shares (thousand)

Earnings per share (yen)

Earnings per share (yen) core basis Dividend per share (yen)

Return on Equity (%) Dividend on Earnings (%)

7. Investment in Property, Plant and Equipment

Depreciation/Amortisation

Investment in Property , Plant and Equipment

ConsolidatedDepreciation (PP&E)

Consolidated

Amortisation of Intangible Assets (incl. software, etc.)

Consolidated

FY20 Full Year

- Investment in Property , Plant and Equipment does not include right-of-use asset

FY21 Full Year

1,835,852

8,778

1,827,074

67.08

103.03

50

8.7%

6.5%

40.0 32.7

33.7

FY21 Full Year

40.1 39.6

30.2

Unit: B¥

Unit: B¥

ForecastsForecastsForecastsForecasts

FY21

FY22 Full Year	Change (%)
1,443.0	11.3%
260.0 18.0%	0.5%
644.2 44.6%	19.9%
339.9 23.6%	7.8%
74.4 5.2%	12.2%
118.5 8.2%	7.7%
6.0 0.4%	-28.1%

1,443.0

260.0

6.0

ForecastsChange fromForecasts

FY21

FY22 Full Year	Change (%)
39.0	29.3%
40.0	-0.1%
42.0	6.0%

39.0

40.0 42.0